A detailed history of Jpmorgan Chase & CO transactions in Castle Biosciences Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 69,409 shares of CSTL stock, worth $2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
69,409
Previous 26,168 165.24%
Holding current value
$2 Million
Previous $569,000 247.8%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$17.4 - $31.47 $752,393 - $1.36 Million
43,241 Added 165.24%
69,409 $1.98 Million
Q2 2024

Aug 12, 2024

SELL
$18.84 - $24.94 $941,529 - $1.25 Million
-49,975 Reduced 65.63%
26,168 $569,000
Q1 2024

May 10, 2024

BUY
$18.06 - $25.3 $465,532 - $652,158
25,777 Added 51.18%
76,143 $1.69 Million
Q4 2023

Feb 12, 2024

SELL
$12.19 - $22.43 $28,000 - $51,521
-2,297 Reduced 4.36%
50,366 $1.09 Million
Q3 2023

Nov 14, 2023

BUY
$13.28 - $20.3 $15,471 - $23,649
1,165 Added 2.26%
52,663 $889,000
Q2 2023

Aug 11, 2023

BUY
$11.66 - $26.0 $83,602 - $186,420
7,170 Added 16.17%
51,498 $706,000
Q1 2023

May 18, 2023

BUY
$19.47 - $28.49 $602,187 - $881,167
30,929 Added 230.83%
44,328 $1.01 Million
Q1 2023

May 11, 2023

SELL
$19.47 - $28.49 $428,320 - $626,751
-21,999 Reduced 62.15%
13,399 $304,000
Q4 2022

Feb 13, 2023

BUY
$18.08 - $30.0 $44,277 - $73,470
2,449 Added 7.43%
35,398 $833,000
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $63,613 - $96,988
2,826 Added 9.38%
32,949 $860,000
Q2 2022

Aug 11, 2022

BUY
$16.0 - $45.99 $92,784 - $266,696
5,799 Added 23.84%
30,123 $661,000
Q1 2022

May 11, 2022

BUY
$33.17 - $46.98 $25,010 - $35,422
754 Added 3.2%
24,324 $1.09 Million
Q4 2021

Feb 10, 2022

BUY
$39.06 - $67.58 $57,691 - $99,815
1,477 Added 6.69%
23,570 $1.01 Million
Q3 2021

Nov 12, 2021

BUY
$60.13 - $77.6 $1.33 Million - $1.71 Million
22,093 New
22,093 $1.47 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $759M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.